MAP4K5 Inhibitors
1 drugsAbout MAP4K5
MAP4K5, a serine/threonine kinase, participates in stress response, inflammation, and cell death pathways. As a member of the MAP4K family, it regulates key signaling cascades within cells. Its involvement in these processes makes it a potential target for drug development.
MAP4K5 is a potential therapeutic target, but currently there is no genetic evidence directly linking it to specific diseases. Further research is needed to investigate the genetic factors influencing MAP4K5 expression and function in disease.
MAP4K5 is targeted by one FDA-approved drug, ZELBORAF, a small molecule developed by Roche for oncology indications. ZELBORAF was first approved in 2011, and no other drugs have been approved since.
Top MAP4K5 Drugs
Roche is the only company with an approved drug targeting MAP4K5.
The lack of competition presents an opportunity for new entrants, but also indicates potential challenges in targeting this kinase.
MAP4K5 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets MAP4K5, using small molecule modality.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing therapies and potentially improve efficacy.
MAP4K5 Clinical Trials 121 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on MAP4K5. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 46 | 28 | 15 | 2 | 65% |
| Phase 2 | 61 | 25 | 14 | 22 | 64% |
| Phase 3 | 10 | 7 | 1 | 2 | 88% |
| Phase 4 | 4 | 2 | 1 | 1 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved MAP4K5 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting MAP4K5. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
MAP4K5 Drug Approval Timeline (2011 - 2011)
The first and only drug targeting MAP4K5, ZELBORAF, was approved in 2011.
The lack of recent approvals suggests a saturated market or challenges in developing effective MAP4K5-targeting drugs, requiring novel approaches.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 66 (13 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on MAP4K5. A trial counts if an approved drug acting on MAP4K5 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.